Your browser is no longer supported. Please, upgrade your browser.
GNVC GenVec, Inc. daily Stock Chart
GNVC [NASD]
GenVec, Inc.
Index- P/E- EPS (ttm)-3.67 Insider Own11.30% Shs Outstand2.36M Perf Week-12.04%
Market Cap15.86M Forward P/E- EPS next Y-2.80 Insider Trans8.99% Shs Float2.09M Perf Month8.04%
Income-8.20M PEG- EPS next Q- Inst Own25.00% Short Float11.99% Perf Quarter-4.00%
Sales0.30M P/S52.86 EPS this Y28.70% Inst Trans59.03% Short Ratio7.25 Perf Half Y74.23%
Book/sh0.26 P/B25.85 EPS next Y- ROA-101.20% Target Price7.00 Perf Year10.16%
Cash/sh1.78 P/C3.78 EPS next 5Y35.00% ROE-178.10% 52W Range2.70 - 10.44 Perf YTD109.35%
Dividend- P/FCF- EPS past 5Y13.50% ROI-153.50% 52W High-33.91% Beta3.31
Dividend %- Quick Ratio2.10 Sales past 5Y-50.80% Gross Margin- 52W Low155.56% ATR0.41
Employees15 Current Ratio2.10 Sales Q/Q-66.70% Oper. Margin- RSI (14)54.21 Volatility6.15% 6.04%
OptionableNo Debt/Eq0.00 EPS Q/Q-74.40% Profit Margin- Rel Volume0.69 Prev Close6.72
ShortableYes LT Debt/Eq0.00 EarningsJun 01 AMC Payout- Avg Volume34.50K Price6.90
Recom3.00 SMA204.40% SMA508.77% SMA20030.88% Volume23,822 Change2.68%
Jan-25-17Downgrade Rodman & Renshaw Buy → Neutral $15 → $7
Dec-02-16Reiterated Rodman & Renshaw Buy $2.30 → $15
Jun-20-16Resumed Rodman & Renshaw Buy $2.30
Feb-24-14Initiated HC Wainwright Buy $9
May-12-17 11:56AM  GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
Apr-23-17 07:35PM  Act Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of GenVec, Inc. - GNVC PR Newswire
Apr-17-17 07:29PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc. GlobeNewswire
Apr-14-17 02:34PM  GenVec investor alleges misleading financial disclosures ahead of Intrexon acquisition American City Business Journals
Mar-20-17 08:35AM  GenVec, Inc. :GNVC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:35AM  GenVec, Inc. :GNVC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 03:09PM  GenVec, Inc. :GNVC-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube -6.89%
03:09PM  GenVec, Inc. :GNVC-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-10-17 01:04PM  GENVEC INC Financials
Mar-06-17 04:32PM  GENVEC INC Files SEC form 10-K, Annual Report
Mar-01-17 05:10PM  Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results PR Newswire
Feb-17-17 05:11PM  Lifshitz & Miller LLP Announces Investigation of Aetna Inc., GenVec, Inc., Ixia, McKesson Corporation, Meridian Bioscience, Inc., Novan, Inc., Regulus Therapeutics Incs., The Southern Company and The Western Union Company PR Newswire
Feb-08-17 06:55PM  WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders PR Newswire
Feb-06-17 05:08PM  INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
11:51AM  Did a Case of Buyer's Remorse Send Intrexon Corporation Down 13% in January? Motley Fool
11:51AM  Did a Case of Buyer's Remorse Send Intrexon Corporation Down 13% in January? at Motley Fool
Feb-02-17 11:41AM  GENVEC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenVec, Inc. PR Newswire
06:00AM  SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
Jan-26-17 03:10PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of GenVec, Inc. to Intrexon Corporation is Fair to Shareholders - GNVC Accesswire
Jan-25-17 10:08AM  Intrexon To Buy GenVec In Stock Deal For $7/Shr at Investopedia
07:07AM  GenVec downgraded by Rodman & Renshaw
Jan-24-17 04:59PM  GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit +44.71%
01:54PM  Intrexon to acquire fellow Md. biotech at bizjournals.com
09:00AM  Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform PR Newswire
Jan-11-17 08:00AM  GenVec to Present at Phacilitate Cell & Gene Therapy World 2017 PR Newswire -25.94%
Jan-10-17 09:30AM  EnteroMedics and GenVec Post Substantial Gains as the NASDAQ is Pushed to Record High Accesswire +76.86%
Jan-05-17 08:00AM  GenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. Louis PR Newswire +21.66%
Dec-16-16 11:35AM  GENVEC INC Files SEC form 8-K, Other Events
Dec-01-16 09:49AM  GENVEC INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financi
07:03AM  Splits Calendar: GenVec splits before market open today (1:10 ratio)
07:00AM  GenVec Effects 1-for-10 Reverse Stock Split PR Newswire
Nov-16-16 04:16PM  GENVEC INC Files SEC form 8-K, Other Events
Nov-07-16 11:49AM  GenVec, Inc. :GNVC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 +16.64%
Nov-04-16 09:53AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:30AM  GenVec Reports Third Quarter 2016 Financial Results PR Newswire
Oct-24-16 04:36PM  GENVEC INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure -5.76%
Sep-28-16 08:00AM  GenVec To Present At 2016 Cell & Gene Meeting On The Mesa PR Newswire
Sep-01-16 06:46AM  GENVEC INC Files SEC form 8-K, Regulation FD Disclosure
Aug-25-16 03:00PM  GenVec faces delisting threat after it fails to raise share price at bizjournals.com
Aug-24-16 07:01AM  GENVEC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
Aug-09-16 12:59PM  GenVec, Inc. :GNVC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
Aug-05-16 10:21AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:30AM  GenVec Reports Second Quarter 2016 Financial Results PR Newswire
Aug-01-16 10:15AM  Can DENTSPLY (XRAY) Spring an Earnings Surprise in Q2?
Jul-27-16 08:01AM  GENVEC INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-25-16 07:30AM  FDA Lifts Clinical Hold On CGF166 PR Newswire
Jun-02-16 11:22AM  GENVEC INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
May-17-16 12:49PM  GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2016 By the Numbers -5.77%
May-12-16 11:14AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -5.19%
08:00AM  GenVec Reports First Quarter 2016 Financial Results PR Newswire
May-10-16 05:48PM  GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Fi +6.28%
May-09-16 08:10AM  7 Stocks Under $10 Spiking Toward Big Gains at TheStreet
May-05-16 08:55AM  GenVec Announces $5 Million At-The-Market Offering PR Newswire -18.73%
May-02-16 09:29AM  GENVEC INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  GenVec Provides Update on Hearing Loss Clinical Program PR Newswire
Mar-14-16 10:49AM  GenVec, Inc. :GNVC-US: Earnings Analysis: Q4, 2015 By the Numbers -5.97%
Mar-09-16 08:01AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +55.07%
07:30AM  GenVec Reports Fourth Quarter and 2015 Year-End Financial Results PR Newswire
07:07AM  Q4 2015 GenVec Inc Earnings Release - Before Market Open
Mar-02-16 08:00AM  GenVec To Release Fourth Quarter And Year-End 2015 Financial Results And Conduct A Conference Call On March 9, 2016 PR Newswire +5.10%
Feb-26-16 05:21PM  GENVEC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
Jan-22-16 04:07PM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements and
Jan-20-16 07:00AM  GenVec Provides Investor Update PR Newswire
Jan-11-16 12:55PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenVec, Inc. (GNVC) -58.67%
08:11AM  GENVEC INC Files SEC form 8-K, Other Events
Jan-07-16 02:51PM  GenVec returns to hearing loss research with new Novartis deal at bizjournals.com
Dec-10-15 11:51AM  GenVec, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-09-15 01:56PM  Is GenVec, Inc. (GNVC) A Good Stock To Buy? at Insider Monkey
Dec-02-15 08:00AM  GenVec Receives Notice of Allowance for Patent Application Providing Broad Protection of Its Gorilla Adenovectors PR Newswire
Nov-16-15 04:45PM  GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; C -7.95%
Nov-09-15 09:57AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  GenVec Reports Third Quarter 2015 Financial Results PR Newswire
Nov-04-15 08:00AM  GenVec Highlights Gorilla Adenovectors At Vaccines R&D-2015 Conference PR Newswire
Oct-02-15 10:51AM  GenVec, Inc. Earnings Q2, 2015
Sep-30-15 08:00AM  GenVec To Present At 2015 Stem Cell Meeting On The Mesa PR Newswire
Sep-28-15 08:00AM  GenVec Expands I.P. Portfolio With Issuance Of U.S. And European Patents For Monkey Adenoviral Vectors PR Newswire
Sep-21-15 08:51AM  GenVec (GNVC) Shows Strength: Stock Moves Up 18.7% -5.82%
Aug-10-15 08:13PM  10-Q for GenVec, Inc. at Company Spotlight
Aug-07-15 10:37AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  GenVec Reports Second Quarter 2015 Financial Results PR Newswire
Jun-03-15 08:00AM  GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines PR Newswire
May-28-15 08:00AM  GenVec To Present At The Jefferies Healthcare Conference PR Newswire +7.31%
May-14-15 08:00AM  GenVec Highlights Proprietary Gorilla Vectors At ASGCT Presentation PR Newswire
May-10-15 08:11PM  10-Q for GenVec, Inc. at Company Spotlight
May-08-15 09:48AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:30AM  GenVec Reports First Quarter 2015 Financial Results PR Newswire
May-01-15 08:11PM  10-K for GenVec, Inc. at Company Spotlight
Apr-23-15 01:57PM  GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-22-15 08:25AM  Michael Richman Appointed To GenVec Board Of Directors at noodls
08:00AM  Michael Richman Appointed To GenVec Board Of Directors PR Newswire
Apr-21-15 08:29AM  GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology at noodls
08:01AM  GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology PR Newswire
Apr-16-15 02:57PM  Bristol-Myers Deal Flags Three Gene-Therapy Picks at Barrons.com
Mar-30-15 09:07AM  GenVec to Release Fourth Quarter and Year-End 2014 Financial Results and Conduct a Conference Call on March 24, 2015 at noodls
09:07AM  GenVec To Present At The 27th Annual ROTH Conference at noodls
09:07AM  GenVec Reports Fourth Quarter And 2014 Year-End Financial Results at noodls
09:07AM  GenVec and TheraBiologics form Collaboration to Develop Neural Stem Cell Mediated Cancer Therapies at noodls
Mar-24-15 10:00AM  GenVec Inc Earnings Call scheduled for 10:00 am ET today
08:40AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q4 2014 GenVec Inc Earnings Release - Before Market Open
GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The company's lead product candidate is CGF166, which is in Phase I/II clinical trial for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to generate vaccine candidates for the prevention of malaria; Laboratory of Malaria Immunology and Vaccinology to create and test various malaria vaccine candidates; and Merial to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MMCAP International Inc. SPC10% OwnerMar 08Buy6.8216,730114,025257,272Mar 14 05:29 PM
MMCAP International Inc. SPC10% OwnerMar 07Buy6.681,1007,346240,542Mar 14 05:29 PM
MMCAP International Inc. SPC10% OwnerMar 06Buy6.742,85719,254239,442Mar 14 05:29 PM
MMCAP International Inc. SPC10% OwnerMar 03Buy6.861,3008,917236,585Mar 14 05:29 PM
Swirsky Douglas JPresident & CEOSep 16Buy0.5010,0005,000252,500Sep 16 03:09 PM